DEXCOM, INC. Equity Securities, FV-NI, Unrealized Loss
DEXCOM, INC. (DXCM) reported Equity Securities, FV-NI, Unrealized Loss of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2020-02-13
- DEXCOM, INC. equity securities, fv-ni, unrealized loss for fiscal 2018 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |